<div id="readability-page-1"><p>Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 7.400-7.650 for the period, compared to the consensus earnings per share estimate of 4.370. The company issued revenue guidance of $225.0 million-$235.0 million, compared to the consensus revenue estimate of $265.2 million.</p><div><p><span></span><span>Get <strong>Ligand Pharmaceuticals</strong> alerts:</span></p></div><h2>Ligand Pharmaceuticals Stock Down 0.1%</h2><p>Shares of NASDAQ LGND opened at $197.17 on Friday. The firm has a 50 day moving average price of $195.10 and a 200 day moving average price of $163.54. The company has a debt-to-equity ratio of 0.47, a quick ratio of 24.30 and a current ratio of 24.69. The stock has a market cap of $3.88 billion, a P/E ratio of 95.25 and a beta of 0.99. Ligand Pharmaceuticals has a 52-week low of $93.58 and a 52-week high of $212.49. </p><p>Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last posted its earnings results on Thursday, November 6th. The biotechnology company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $1.96 by $1.13. The company had revenue of $86.89 million for the quarter, compared to analyst estimates of $58.71 million. Ligand Pharmaceuticals had a net margin of 19.34% and a return on equity of 5.71%. The business's revenue for the quarter was up 123.0% compared to the same quarter last year. During the same period last year, the business posted $1.84 earnings per share. Ligand Pharmaceuticals has set its FY 2025 guidance at 7.400-7.650 EPS.  Analysts expect that  Ligand Pharmaceuticals will post 1.73 EPS for the current year. </p><h2>Analyst Ratings Changes</h2><p>A number of equities research analysts recently issued reports on the company. Citigroup assumed coverage on Ligand Pharmaceuticals in a research report on Tuesday, December 9th. They issued a &#34;buy&#34; rating and a $270.00 target price on the stock. Oppenheimer raised their price target on shares of Ligand Pharmaceuticals from $190.00 to $250.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, November 3rd. Stifel Nicolaus lifted their price objective on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, December 10th. Royal Bank Of Canada boosted their price objective on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, December 10th. Finally, HC Wainwright raised their target price on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating and one  has assigned  a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $239.33.</p><p><b>View Our Latest Report on LGND</b></p><h2>Insider Buying and Selling at Ligand Pharmaceuticals</h2><p>In other news, CFO Octavio Espinoza sold 1,804 shares of Ligand Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $188.31, for a total value of $339,711.24. Following the completion of the transaction, the chief financial officer owned 26,186 shares of the company's stock, valued at $4,931,085.66. This trade represents a 6.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John W. Kozarich sold 467 shares of the company's stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $195.84, for a total value of $91,457.28. Following the completion of the sale, the director owned 44,121 shares in the company, valued at $8,640,656.64. This represents a 1.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,205 shares of company stock valued at $604,187 over the last three months. 7.00% of the stock is owned by company insiders. </p><h2>Institutional Trading of Ligand Pharmaceuticals</h2><p>Several institutional investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC increased its position in  Ligand Pharmaceuticals by 86.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company's stock worth $26,000 after buying an additional 69 shares during the period.  JPL Wealth Management LLC bought a new stake in shares of  Ligand Pharmaceuticals in the third quarter valued at about $52,000.  Tower Research Capital LLC TRC increased its position in  Ligand Pharmaceuticals by 1,656.8% during the second quarter. Tower Research Capital LLC TRC now owns 1,669 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 1,574 shares during the period.  Evergreen Capital Management LLC bought a new stake in  Ligand Pharmaceuticals in the 2nd quarter valued at about $205,000.  Finally, Mackenzie Financial Corp acquired a new position in shares of  Ligand Pharmaceuticals during the 3rd quarter worth approximately $207,000. 91.28% of the stock is currently owned by institutional investors. </p><h2>About Ligand Pharmaceuticals</h2> (Get Free Report)<p>Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.  </p><p>The company's product offerings center around several core platforms.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Ligand Pharmaceuticals</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?</h2><p>Before you consider Ligand Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.</p><p>While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LGND

<p>Ligand Pharmaceuticals updated its FY 2025 earnings guidance, projecting EPS of 7.400-7.650, surpassing the consensus estimate of 4.370. Revenue guidance is set at $225-$235 million, below the consensus of $265.2 million. The stock opened at $197.17, with a market cap of $3.88 billion. Analysts have issued a "Moderate Buy" rating with a consensus price target of $239.33. Insider trading activity includes sales by CFO Octavio Espinoza and Director John W. Kozarich.</p>

Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance